Polymorphisms of p53, GSTM1 and GSTT1, and HPV in uterine cervix adenocarcinoma

Objective: To analyze the participation of glutathione-S-transferase (GST) M I and T I polymorphisms associated protein p53 polymorphism at codon 72 and in the presence of HPV in the carcinogenesis of uterine cervix adenocarcinoma. Methods: Forty-three samples of uterine cervix adenocarcinoma were studied and 86 samples of endocervical cells of women without tumors formed the control group. The presence of HPV was determined in order to genotype the isoforms of p53 at codon 72, GSTM1. GSTM1*0, GSTT1 and GSTT1*0 which were evaluated by the PCR method. Results: HPV was present in 97.67% of the adenocarcinoma cases and in 31.40% of the control group. Statistical analysis showed differences (p = 0.001) and an OR of 113.3 (CI 95%: 13.67-947.14). GSTT1 and GSTT1*0 analysis showed a significant difference between the groups (p = 0.001) with an OR of 4.58 (CI 95%: 2.041-10.28) (p < 0.001) for the presence of GSTT1*0. When it was associated with HPV OR was 6.6 (CI 95%: 0.04-0.50). Analyses of p53 and GSTM1 and GSTM1*0 either alone or associated with HPV were not significant. Conclusion: The presence of GSTT1*0 increased the risk for uterine cervix adenocarcinoma development while the allele GSTT1 had it protective action. The other isoforms did not appear to participate in the carcinogenesis of uterine cervix adenocarcinoma.

p53; GSTM1; GSTT1; HPV; Adenocarcinoma

[1] Romero R., Kuivaniemi H., Tromp G., Olson J.N.: “The design, execution, and interpretation of genetic association studies to decipher complex diseases”. Am. J. Obstet. Gynecol., 2002, 187, 1299.

[2] Storey A., Thomas M., Kalita A. et al.: “Role of a p53 polymorphism in the development of human papillomavirus-associated cancer”. Nature, 1998, 393, 229.

[3] Ueda M., Terai Y., Kanda K. et al.: “Germline plymorphism of p53 codon 72 in gynecological cancer”. Gynecol. Oncol., 2006, 100, 173.

[4] Haupt S., Berge M., Goldberg Z., Haupt Y.: “Apoptosis – the p53 network”. J. Cell Sci., 2003, 116, 4077.

[5] Pietsch E.C., Humbey O., Murphy M.E.: “Polymorphisms in the p53 pathway”. Oncogene, 2006, 25, 1602.

[6] Xu C., Li C.Y.-T., Kong A.-N.T.: “Induction of phase I, II and III drug metabolism/transport by xenobiotics”. Arch. Pharm. Res., 2005, 28, 249.

[7] Hayes J.D., Flanagan J.U., Jowsey I.R.: “Glutathione Transferase”. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 51.

[8] Frova C.: “Glutathione transferase in genomics era: news insights and perspectives”. Biomol. Eng., 2006, 23, 149.

[9] Parl F.F.: “Glutathione S-transferase genotype and cancer risk”. Cancer Lett., 2005, 221, 123.

[10] Rebbeck T.R.: “Molecular epidemiology of the human glutathione- S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility”. Cancer Epidemiol. Biomarker. Prev., 1997, 6, 733.

[11] Habdous M., Siest G., Herbeth B., Vincent-Viry M., Visvikis S.: “Polymorphismes des glutathion S-transferases et pathologies humaines: bilan des études épidémiologiques”. Ann. Biol. Clin., 2004, 62, 15.

[12] Goodman M.T., McDuffie K., Hernandez B., Bertram C.C., Wilkens L.R., Guo C. et al.: “CYP1A1, GSTM1, and GSTT1, polymorphisms and risk of cervical squamous intraepithelial lesions in a multiethnic population”. Gynecol. Oncol., 2001, 81, 263.

[13] Au W.W., Sierra-Torres C.H., Tyring S.K.: “Acquired and genetic susceptibility to cervical cancer”. Mutat. Res., 2003, 544, 361.

[14] Lee S.A., Kim J.W., Roh J.W., Choi J.Y., Lee K.-M., Yoo K.Y. et al.: “Genetic polymorphisms of GSTM1, p21, p53 and HPV infection with cervical cancer in Korean women”. Gynecol. Oncol., 2004, 93, 14.

[15] Sharma A., Sharma J.K., Murthy N.S., Mitra A.B.: “Polymorphisms at GSTM1 and GSTT1 gene loci and susceptibility to cervical cancer in Indian population”. Neoplasma, 2004, 51, 12.

[16] Haverkos H., Rohrer M., Pickworth W.: “The cause of invasive cervical cancer could de multifactorial”. Biomed. Pharmacoter., 2000, 54, 54.

[17] Pirog E.C., Kleter B., Olgac S., Bobkiewicz P., Lindeman J., Quint W.G. et al.: “Prevalence of human papillomavirus DNA in difference histological subtype of cervical adenocarcinoma”. Am. J. Pathol., 2000, 157, 1055.

[18] Danaei G., Hoorn S.V., lopez A.D., Murray C.J., Ezzati M.: “Comparative Risk Assessment Collaborating Group. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors”. Lancet, 2005, 366, 1784.

[19] Castellsagué X., Díaz M., Sanjosé S., Muñoz N., Herrero R., Franceschi S. et al.: “Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention”. J. Natl. Cancer Inst., 2006, 98, 303.

[20] Altekruse S.F., Lacey J.V. Jr., Brinton L.A., Gravitt P.E., Silverberg S.G., Barners W.A. Jr.: “Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinomas and squamous cell carcinoma: Northeastern United States”. Am. J. Obstet. Gynecol., 2003, 188, 657.

[21] Ayhan A., Al R.A., Baykal C., Demirtas E., Yüce K., Ayhan A.: “A comparison of prognoses of FIGO stage IB adenocarcinoma and squamous cell carcinoma”. Int. J. Gynecol. Cancer, 2004, 14, 279.

[22] Recoules-Arche A., Rouzier R., Rey A., Villefranque V., Haie-Meder C., Pautier P. et al.: “Les adenocarcinomas du col utérin ont-ils plus mauvais prognostic que les carcinomas épidermoïdes?”. Gynecol. Obstet. Fertil., 2004, 32, 116.

[23] Chao A., Wang T.H., Lee Y.S., Hsueh S., Chao A.S., Chang T.C. et al.: “Molecular characterization of adenocarcinoma and squamous carcinoma of the uterine cervix using microarray analysis of gene expression”. Int. J. Cancer, 2006, 119, 91.

[24] Cawkwell L., Quirke P.: “Direct multiplex amplification of DNA from a formalin fixed, paraffin wax embedded tissue”. Mod. Pathol., 2000, 53, 51.

[25] Morgan K., Lam L., Kalsheker N.: “A rapid and efficient method for DNA extraction from paraffin wax embedded tissue for PCR amplification”. J. Clin. Pathol. Mol. Pathol., 1996, 49, M179.

[26] Manos M.M., Ting Y., Wright D.K., Lewis A.J., Broke T.R., Wolinsky S.M.: “Use of polymerase amplification for the detection of genital human papillomaviruses”. Cancer Cells, 1989, 7, 209.

[27] Soulitzis N., Sourvinos G., Dokiniakis D.N., Spandidos D.A.: “p53 codon 72 polymorphism and its association with bladder cancer”. Cancer Lett., 2002, 179, 175.

[28] Ueda M., Hung Y.C., Terai Y., Saito J., Nunobiki O., Noda S. et al.: “Glutathione-S-transferase and p53 polymorphisms in cervical carcinogenesis”. Gynecol. Oncol., 2005, 96, 736.

[29] Bulk S., Visser O., Rozendaal L., Verheijen R.H., Meijer C.J.: “Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area”. Br. J. Cancer, 2003, 89, 834.

[30] Lea J.S., Sheets E.E., Wenham R.M., Duska L.R., Coleman R.L., Miller D.S. et al.: “Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival”. Gynecol. Oncol., 2002, 84, 115.

[31] Baalbergen A., Ewing-Graham P.C., Hop W.C., Struijk P., Helmerhorst T.J.: “Prognostic factors in adenocarcinomas of uterine cervix”. Gynecol. Oncol., 2004, 92, 262.

[32] Hildesheim A., Schiffman M., Brinton L., Fraumeni J.F. Jr., Herrero R., Bratti M.C.: “p53 polymorphism and risk of cervical cancer”. Nature, 1998, 396, 531.

[33] Gustafsson A.C., Guo Z., Hu X., Ahmadian A., Brodin B., Nilsson A. et al.: “HPV-related cancer susceptibility and p53 codon 72 plymorphism”. Acta Derm. Venerol., 2001, 81, 125.

[34] Andersson S., Rylander E., Strand A., Sällström J., Wilander E.: “The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas”. Br. J. Cancer, 2001, 85, 1153.

[35] Yang Y.C., Chang C.L., Chen M.L.: “Effect of p53 polymorphism on the susceptibility of cervical cancer”. Gynecol. Obstet. Invest., 2001, 51, 197.

[36] Newton-Cheh C., Hirchhorn J.N.: “Genetic association studies of complex traits design and analysis issues”. Mutat. Res., 2005, 573, 54.